Cytosorbents Corporation (CTSO)
Cytosorbents Statistics
Share Statistics
Cytosorbents has 54.83M shares outstanding. The number of shares has increased by 5.02% in one year.
| Shares Outstanding | 54.83M |
| Shares Change (YoY) | 5.02% |
| Shares Change (QoQ) | 0.74% |
| Owned by Institutions (%) | 28.15% |
| Shares Floating | 44.16M |
| Failed to Deliver (FTD) Shares | 1.6K |
| FTD / Avg. Volume | 0.65% |
Short Selling Information
The latest short interest is 1.83M, so 3.34% of the outstanding shares have been sold short.
| Short Interest | 1.83M |
| Short % of Shares Out | 3.34% |
| Short % of Float | 4.16% |
| Short Ratio (days to cover) | 3.33 |
Valuation Ratios
The PE ratio is -1.74 and the forward PE ratio is -7.14. Cytosorbents's PEG ratio is 0.12.
| PE Ratio | -1.74 |
| Forward PE | -7.14 |
| PS Ratio | 1.36 |
| Forward PS | 0.5 |
| PB Ratio | 2.13 |
| P/FCF Ratio | -2.19 |
| PEG Ratio | 0.12 |
Enterprise Valuation
Cytosorbents Corporation has an Enterprise Value (EV) of 53.75M.
| EV / Earnings | -1.89 |
| EV / Sales | 1.48 |
| EV / EBITDA | -1.84 |
| EV / EBIT | -1.72 |
| EV / FCF | -2.38 |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of 0.79.
| Current Ratio | 1.77 |
| Quick Ratio | 1.51 |
| Debt / Equity | 0.79 |
| Total Debt / Capitalization | 44.03 |
| Cash Flow / Debt | -1.18 |
| Interest Coverage | -197.66 |
Financial Efficiency
Return on equity (ROE) is -1.22% and return on capital (ROIC) is -72.96%.
| Return on Equity (ROE) | -1.22% |
| Return on Assets (ROA) | -0.54% |
| Return on Capital (ROIC) | -72.96% |
| Revenue Per Employee | $195,426.77 |
| Profits Per Employee | $-153,265.56 |
| Employee Count | 186 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 3.79 |
Taxes
| Income Tax | -813.74K |
| Effective Tax Rate | 0.03 |
Stock Price Statistics
The stock price has increased by 6.32% in the last 52 weeks. The beta is 0.78, so Cytosorbents's price volatility has been higher than the market average.
| Beta | 0.78 |
| 52-Week Price Change | 6.32% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 44.02 |
| Average Volume (20 Days) | 246.06K |
Income Statement
In the last 12 months, Cytosorbents had revenue of 36.35M and earned -28.51M in profits. Earnings per share was -0.64.
| Revenue | 36.35M |
| Gross Profit | 22.39M |
| Operating Income | -31.21M |
| Net Income | -28.51M |
| EBITDA | -29.18M |
| EBIT | -31.21M |
| Earnings Per Share (EPS) | -0.64 |
Balance Sheet
The company has 14.13M in cash and 18.31M in debt, giving a net cash position of -4.18M.
| Cash & Cash Equivalents | 14.13M |
| Total Debt | 18.31M |
| Net Cash | -4.18M |
| Retained Earnings | -282.51M |
| Total Assets | 47.8M |
| Working Capital | 8.17M |
Cash Flow
In the last 12 months, operating cash flow was -21.66M and capital expenditures -936.24K, giving a free cash flow of -22.59M.
| Operating Cash Flow | -21.66M |
| Capital Expenditures | -936.24K |
| Free Cash Flow | -22.59M |
| FCF Per Share | -0.51 |
Margins
Gross margin is 61.6%, with operating and profit margins of -85.86% and -78.43%.
| Gross Margin | 61.6% |
| Operating Margin | -85.86% |
| Pretax Margin | -80.66% |
| Profit Margin | -78.43% |
| EBITDA Margin | -80.28% |
| EBIT Margin | -85.86% |
| FCF Margin | -62.15% |
Dividends & Yields
CTSO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -63.37% |
| FCF Yield | -40.79% |
Analyst Forecast
The average price target for CTSO is $6.5, which is 543.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.5 |
| Price Target Difference | 543.6% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Dec 5, 2014. It was a backward split with a ratio of 1:25.
| Last Split Date | Dec 5, 2014 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -8.24 |
| Piotroski F-Score | 3 |